Summary: The paper discusses the most important updates that have been made in the latest version of the Global Initiative for Asthma report in 2018. The authors follow the changes in subsequent chapters in detail and highlight the most important elements of the guidelines. As the most important they consider the appearance of recommendations for benralizumab in the treatment of severe eosinophilic asthma. Other changes bring greater order to the previous guidelines.